Premium
O1‐02‐01: IMAGING TAU PATHOLOGY IN VIVO IN FTLD: INITIAL EXPERIENCE WITH [18F] T807 PET
Author(s) -
Dickerson Brad,
DomotoReilly Kimiko,
Daisy Sapolsky,
Brickhouse Michael,
Stepanovic Michael,
Johnson Keith
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.04.062
Subject(s) - progressive supranuclear palsy , neuroscience , pathology , primary progressive aphasia , brainstem , atrophy , basal ganglia , cerebellum , white matter , psychology , asymptomatic , neuroimaging , temporal lobe , temporal cortex , medicine , dementia , frontotemporal dementia , magnetic resonance imaging , central nervous system , radiology , disease , epilepsy
OBJECTIVE: To image tau pathology in vivo using PET in patients with Frontotemporal Lobar Degeneration (FTLD) BACKGROUND: A critical unmet need for FTLD research, especially therapeutic trials, is the development of biomarkers to distinguish FTLD-tau from FTLD-TDP and other non-tau FTLD pathologies. DESIGN/METHODS: We used [18F] T807, a novel PET ligand, to scan a series of patients with FTLD, including one MAPT P301L mutation carrier with moderate severity FTD dementia, an asymptomatic carrier of the same mutation, and a patient with sporadic mild progressive agrammatic aphasia. We analyzed SUVR (cerebellum reference) data to localize and quantify [18F] T807 signal. We also co-registered analyzed [18F] T807 images to MRI images for visualization and calculation of % atrophy relative to controls. RESULTS: [18F] T807 signal was elevated in frontal, insular, and anterior temporal cortex in symptomatic patients, and colocalized with atrophy. In the aphasic patient, [18F] T807 signal was highest in inferior frontal and middle temporal gyri and temporal pole with marked asymmetry, most prominent in the dominant hemisphere, and localized remarkably well with atrophy. The asymptomatic carrier had mildly elevated signal in frontal, insular, and anterior temporal cortex as well as white matter. CONCLUSIONS: T807 is a promising new PET ligand for imaging tau pathology in vivo in patients with FTLD. Study Supported by: Funding: R21NS084156, R21NS077059, P50-AG005134 Disclosure: Dr. Dickerson has received personal compensation for activities with Pfizer Inc and En Vivo as a consultant. Dr. Hochberg has nothing to disclose. Dr. Brickhouse has nothing to disclose. Dr. Stepanovic has nothing to disclose. Dr. Johnson has received personal compensation for activities with General Electric Healthcare, Avid Radiopharmaceuticals Inc., Siemens, and Genzyme Corp. Dr. Johnson has received personal compensation in an editorial capacity for American Society of Neuroimaging. Dr. Johnson has received research support from Avid Radiopharmaceuticals Inc., Janssen, and Pfizer Inc.